( d on data from seven clinical trialsin...)New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension,Health

d on data from seven clinical trials involving more than 6,200 patients[4], including the data presented at the ASH meeting. Submissions were made for four different dosage combinations of Tekturna and Hydrochlorothiazide: 150/12.5 mg tablets, 150/25 mg tablets, 300/12.5 mg tablets and 300/25 mg tablets.

Speedel was the first company to demonstrate the benefits of combining a renin inhibitor with a diuretic during its pilot clinical development programme of SPP100 between 2000-2002 [5].

Mr Ben Tan, Speedel Head of Business Development & Licensing commented "In the antihypertensive drug market, the most commonly prescribed fixed combinations contain a diuretic. It is rewarding to know that subject to FDA approval, patients may soon benefit from Tekturna HCT which will increase convenience and compliance, therefore resulting in better control of blood pressure".

Highlights of data presented at ASH

1. Patients treated for 6 months with SPP100 as monotherapy or in co-administration with a diuretic HCTZ showed sustained reductions in blood pressure (BP) and plasma renin activity (PRA), even though plasma renin concentration (PRC) remained elevated. These reductions in BP and PRA were greater than for those patients treated with ramipril (ACE-I[4]) who also showed elevated PRC (Poster P - 445).

2. Two weeks and four weeks after patients stopped receiving SPP100 based therapy, they still showed persistent reductions in BP and PRA respectively, compared to those patients who were taken off ramipril (ACE-I) therapy (Poster P- 445).

3. Patients treated for 12 months with SPP100 as monotherapy or in co-administration with amlodipine (CCB[5]) showed sustained reductions in blood pressure (BP) and plasma renin activity (PRA), while plasma renin concentration (PRC) was stable essentially at the same level after 12 months as it was after 6 months. In contrast, patients treated with a diuretic HCTZ showed increased PRA (Poster P- 421).<
'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development